Galectin Therapeutics Inc. (GALT) Cash Flow Statement
Where GALT’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$23.9M
- Capital expenditures
- $0
- Free cash flow
- −$23.9M
- Returned to shareholders
- $138,000
- Change in cash
- $2.6M cash at year-end $17.7M
Drawn to scale: where the cash came from and how it was used. Hover for values.
GALT operating cash flow, capex and free cash flow
GALT cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$16.4M2016 | −$23.9M2025 | — | |
| Capital expenditures | $02016 | $02025 | — | |
| Free cash flow | −$16.4M2016 | −$23.9M2025 | — | |
| Stock-based compensation | $2.5M2016 | $1.7M2025 | −4.4%/yr | |
| Dividends paid | $741,0002016 | $138,0002025 | −17.0%/yr | |
| Share buybacks (net) | $02016 | $02025 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GALT cash flow by activity
GALT net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
GALT cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$30.8M | −$47.0M | −$41.1M | −$38.8M | −$30.5M | −$23.5M | −$13.3M | −$13.9M | −$16.2M | −$21.4M |
| Depreciation & amortization | $53,000 | $37,000 | $33,000 | $32,000 | $41,000 | $36,000 | $35,000 | $1,000 | $1,000 | $7,000 |
| Stock-based compensation | $1.7M | $2.4M | $2.3M | $2.9M | $2.1M | $1.8M | $1.7M | $4.4M | $1.1M | $2.5M |
| Change in working capital | $609,000 | $2.3M | $4.7M | $5.0M | $3.8M | $942,000 | $641,000 | −$1.1M | −$804,000 | $2.5M |
| Other non-cash items | $4.6M | $512,000 | $1.1M | −$147,000 | $351,000 | $87,000 | $87,000 | $347,000 | $45,000 | $0 |
| Cash from operating activities | −$23.9M | −$41.8M | −$33.0M | −$31.1M | −$24.3M | −$20.6M | −$10.8M | −$10.2M | −$15.9M | −$16.4M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions & other investing | — | — | — | — | — | — | — | — | $0 | $0 |
| Cash from investing activities | — | — | — | — | — | — | — | — | $0 | $0 |
| Financing activities | ||||||||||
| Dividends paid | −$138,000 | −$91,000 | −$120,000 | −$97,000 | −$171,000 | −$137,000 | −$394,000 | −$915,000 | −$1.2M | −$741,000 |
| Share repurchases & issuance (net) | $667,000 | $845,000 | $671,000 | $899,000 | −$30.0M | $263,000 | $50.5M | $15.4M | $696,000 | $5.9M |
| Net borrowing (repayment) | $21.0M | $30.0M | $30.0M | $10.0M | $30.0M | $30.0M | $30.0M | $30.0M | — | — |
| Shares issued | $3.2M | $0 | $0 | $0 | $6.8M | $263,000 | $50.5M | $15.4M | $0 | $0 |
| Other financing | $1.7M | $473,000 | $9.5M | −$802,000 | $30.2M | −$30.1M | −$80.5M | −$44.5M | $4.1M | $741,000 |
| Cash from financing activities | $26.5M | $31.2M | $40.0M | $10.0M | $36.8M | $263,000 | $50.1M | $15.4M | $3.6M | $5.9M |
| Summary | ||||||||||
| Net change in cash | $2.6M | −$10.5M | $7.1M | −$21.1M | $12.5M | −$20.3M | $39.2M | $5.2M | −$12.3M | −$10.5M |
| Cash at end of period | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M | $27.1M | $47.5M | $8.3M | $3.1M | $15.4M |
| Free cash flow | −$23.9M | −$41.8M | −$33.0M | −$31.1M | −$24.3M | −$20.6M | −$10.8M | −$10.2M | −$15.9M | −$16.4M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$9.1M | −$5.0M | −$5.5M | −$8.2M | −$7.5M | −$9.6M | −$12.0M | −$11.2M | −$12.4M | −$11.5M | −$10.0M | −$10.4M |
| Depreciation & amortization | $4,000 | $12,000 | $41,000 | $0 | $2,000 | $10,000 | $10,000 | $9,000 | $9,000 | $9,000 | $9,000 | $8,000 |
| Stock-based compensation | $963,000 | $686,000 | $195,000 | $496,000 | $500,000 | $468,000 | $590,000 | $515,000 | $738,000 | $604,000 | $497,000 | $586,000 |
| Change in working capital | $2.5M | $1.3M | −$1.2M | $1.7M | −$1.0M | $1.1M | $326,000 | $1.1M | $3.1M | −$2.3M | $4.9M | $1.5M |
| Other non-cash items | $3.2M | −$827,000 | $403,000 | $2.4M | $1.4M | $372,000 | −$1.8M | $1.0M | $141,000 | $1.1M | −$145,000 | $682,000 |
| Cash from operating activities | −$2.4M | −$3.9M | −$6.0M | −$3.5M | −$6.6M | −$7.7M | −$12.8M | −$8.5M | −$8.3M | −$12.1M | −$4.7M | −$7.6M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | ||||||||||||
| Dividends paid | — | −$61,000 | −$62,000 | −$14,000 | — | −$62,000 | −$73,000 | −$18,000 | — | −$72,000 | −$120,000 | — |
| Share repurchases & issuance (net) | — | — | $219,000 | $213,000 | — | — | — | $568,000 | — | $277,000 | $374,000 | — |
| Net borrowing (repayment) | — | — | $10.0M | $0 | $11.0M | $0 | $0 | $10.0M | — | — | — | — |
| Shares issued | $0 | $0 | $1.2M | $853,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $1.6M | $318,000 | $916,000 | $244,000 | $1.9M | $62,000 | $924,000 | −$550,000 | $10.4M | $9.8M | $9.7M | $10.0M |
| Cash from financing activities | $1.6M | $257,000 | $12.2M | $1.3M | $12.9M | $0 | $851,000 | $10.0M | $10.4M | $10.0M | $10.0M | $10.0M |
| Summary | ||||||||||||
| Net change in cash | −$842,000 | −$3.6M | $6.2M | −$2.2M | $6.3M | −$7.7M | −$11.9M | $1.5M | $2.0M | −$2.1M | $5.3M | $2.4M |
| Cash at end of period | $13.3M | $14.1M | $17.7M | $11.5M | $13.8M | $7.4M | $15.1M | $27.1M | $25.6M | $23.6M | $25.7M | $20.4M |
| Free cash flow | −$2.4M | −$3.9M | −$6.0M | −$3.5M | −$6.6M | −$7.7M | −$12.8M | −$8.5M | −$8.3M | −$12.1M | −$4.7M | −$7.6M |
| Free cash flow margin | — | — | — | — | — | — | −35,530.6% | — | — | — | −5,877.5% | — |
| Capex / revenue | — | — | — | — | — | — | 0.0% | — | — | — | 0.0% | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
GALT cash generation
In fiscal 2025 (ended December 31, 2025), Galectin Therapeutics generated -$23.9 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$23.9 million. It returned $0.1 million to shareholders through dividends ($0.1 million) and net share buybacks ($0). Cash and equivalents rose by $2.6 million over the year.
Related: GALT income statement, GALT balance sheet. See the GALT stock overview for the latest quote and news.
GALT cash flow FAQ
What is Galectin Therapeutics's free cash flow?
Galectin Therapeutics's free cash flow was -$23.9 million in fiscal 2025: -$23.9 million of operating cash flow minus $0 of capital expenditures It was -$41.8 million a year earlier..
How much cash does Galectin Therapeutics generate from operations?
Galectin Therapeutics generated -$23.9 million of cash from operating activities in fiscal 2025.
How much does Galectin Therapeutics pay in dividends?
Galectin Therapeutics paid $0.1 million in dividends in fiscal 2025.